347,022 Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 21.7% during the third quarter, Holdings Channel reports. The firm owned 1,944,020 shares of the company’s stock after acquiring an additional 347,022 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Ionis Pharmaceuticals were worth $87,249,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. AlphaCentric Advisors LLC increased its stake in Ionis Pharmaceuticals by 4.8% in the 3rd quarter. AlphaCentric Advisors LLC now owns 16,163 shares of the company’s stock worth $722,000 after acquiring an additional 733 shares during the last quarter. Privium Fund Management B.V. boosted its position in shares of Ionis Pharmaceuticals by 9.1% during the 3rd quarter. Privium Fund Management B.V. now owns 349,003 shares of the company’s stock valued at $15,583,000 after acquiring an additional 29,079 shares during the last quarter. CenterBook Partners LP boosted its position in shares of Ionis Pharmaceuticals by 25.7% during the 3rd quarter. CenterBook Partners LP now owns 112,240 shares of the company’s stock valued at $5,012,000 after acquiring an additional 22,960 shares during the last quarter. Pekin Hardy Strauss Inc. purchased a new position in shares of Ionis Pharmaceuticals in the third quarter valued at $372,000. Finally, Provenance Wealth Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals in the third quarter valued at $241,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Performance

Shares of Ionis Pharmaceuticals stock opened at $31.00 on Tuesday. The stock’s fifty day moving average is $46.20 and its two-hundred day moving average is $65.63. The company has a market capitalization of $5.15 billion, a PE ratio of -8.96 and a beta of 0.43. The company has a quick ratio of 7.73, a current ratio of 7.89 and a debt-to-equity ratio of 3.07. Ionis Pharmaceuticals, Inc. has a 52 week low of $27.75 and a 52 week high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%. The business had revenue of $242.72 million for the quarter, compared to analyst estimates of $178.17 million. During the same quarter last year, the firm posted ($0.80) earnings per share. The business’s revenue was up 54.8% compared to the same quarter last year. As a group, analysts expect that Ionis Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IONS. Oppenheimer restated an “outperform” rating and set a $85.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, September 24th. Royal Bank Of Canada dropped their price target on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Barclays dropped their target price on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Wolfe Research downgraded Ionis Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Nineteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $88.29.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose about 55% year over year to $242.7 million, exceeding estimates, while the per-share loss was narrower than analysts expected. Ionis Q3 earnings report
• Positive Sentiment: DAWNZERA sales increased 40% to $37 million in the third quarter, offering a bright spot in the commercial portfolio. Ionis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: The main setback was TRYNGOLZA: Ionis cut its 2026 sales forecast to about $50 million from its prior $100 million–$110 million outlook, citing slower uptake and competitive pressure. The reduction has raised concerns about the drug’s launch and the company’s growth prospects. Ionis Slashes Key Drug Revenue Outlook by 50%
• Negative Sentiment: Ionis forecast 2026 revenue of $875 million–$900 million, below the roughly $920.8 million analyst consensus, adding to the concerns despite the quarterly beat. Ionis Q3 Revenue Rises; Lowers TRYNGOLZA Sales Outlook
• Neutral Sentiment: Law firms announced investigations following the guidance reduction. These are allegations and inquiries, not findings of wrongdoing, but may add uncertainty for investors. Investor investigation notice

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Shannon Devers sold 1,357 shares of the firm’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.81% of the company’s stock.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases.

Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.